Navigation Links
Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
Date:3/8/2013

DALLAS, March 8, 2013 /PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a U.S. Company specializing in cannabinoid formulation-based health solutions through its Phytiva brand product lines is pleased that in the last two days, medical cannabis bills have easily advanced out of key committees to full votes in both the Illinois General Assembly and the New Hampshire House of Representatives.  These actions toward providing safe access to medical cannabis for people with unmet medical needs in both Illinois with House Bill 0030 and New Hampshire with House Bill 442-FN continue the trend of state-by-state recognition of the medical value of cannabis and cannabinoids.

Currently 18 states and the District of Columbia have enacted laws which approve and regulate the use medical cannabis, two of which are considering expansion of existing law.  In addition to Illinois and New Hampshire, another 17 states have pending legislation to enact a form of legal protection for medicinal cannabis patients.  Recent national polls show that approximately 80% of Americans are in favor of medicinal cannabis legalization.

"We are incredibly encouraged that more than two-thirds of U.S. states have adopted laws or are formally considering bills to help patients in need of medical cannabis for their ailments.  We commend the most recent bipartisan developments in Illinois and New Hampshire.  As more and more jurisdictions provide legal safe access frameworks, the Company intends to enter these markets, not only in the United States but also abroad, with its Phytiva brand product lines," stated Robert Kane , President and CEO of X-Change Corp.

About Phytiva Brand Product Lines

Phytiva expects to develop and launch various innovative product lines.  The first is the Phytiva Brand European Line, which is an inventive line that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a cannabinoid based product line, utilizing the unique and potent benefits of cannabinoids.  Phytiva's revolutionary formulations target not just the symptom, but also the cause.  Cannabinoids and their sources constitute an ideal base for therapeutic solutions and have been utilized for centuries in skin and other remedies for human ailments.

About The X-Change Corporation

X-Change Corp. is a U.S. Company specializing in cannabinoid based extracts and products that target medical cannabis, nutraceutical, cosmeceutical, and social usage solutions through multiple Phytiva Brand product lines, products, and services. These new Phytiva lines will be launched with cannabinoid based formulations through the launching of a combination of retail and wholesale products, medical cannabis dispensaries, cannabis research in clinics and laboratories, and other legal state and foreign grow operations, on a jurisdiction by jurisdiction approved basis.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

X-Change Corp.

President & CEO

Robert Kane

info@phytiva.com

www.phytiva.com

1.866.326.5595


'/>"/>
SOURCE X-Change Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Biosimilars: A return to optimism?
2. Revenue Growth Optimism in Pharmaceutical Industry: 2013 Survey Reports at RnRMarketResearch.com
3. Rapid Fire Marketing: CANNAcig to Sponsor Medical Cannabis Cup 2012 in San Francisco
4. Cannabis Science Gets Set to Release "Phytiva" Its Newest Brand of Over-the-Counter Skin and Nutraceutical Product Lines Through its Newest Venture Phytiva Pharmaceuticals Inc.
5. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
6. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
7. New Study Shows Cannabis Effects on Driving Skills
8. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Phreesia identifies over 26% of patients who require additional autism evaluation
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, Inc. ... genome editing, announced that the U.S. Food and ... New Drug (IND) application for SB-318, a single ... for Mucopolysaccharidosis Type I (MPS I). The SB-318 ... to initiate a Phase 1/2 clinical study (SB-318-1502) ...
(Date:2/8/2016)... , February 8, 2016 ... new report published by Allied Market Research titled, ... Opportunities and Forecasts, 2014-2020", estimates the world synthetic ... Nucleotide synthesis and sequencing technology segment would continue ... and software tools segment, collectively, held around half ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, PLC, ... eine Infografik mit dem Titel „Epilepsy Around ... mit der der Krankheit gegenüber ein größeres ... ermutigen soll, Medikamentenresistenz bei Epilepsie auf dem ... Diskussion zu machen. Mithilfe der neuen Infografik ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Local insurance agency Dennis Fuller & ... has initiated a fundraiser for a two year old little girl named Bella, ... To support this beautiful child who is facing life’s journey without her loving ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... frequently. While a significant number of women and men with eating disorders report ... itself, that best predicts the development of an eating disorder. , At ...
(Date:2/8/2016)... ... 2016 , ... Discover the Rocky Mountain region’s longest running and impressive garden ... Attendees also get to see the most incredible gardens and home improvement experts that ... the Colorado Convention Center - 700 14th St. Denver CO, is an exciting event ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... share this important news! AHCC and the Home Health and Hospice ICD-10 Transition ... designee for official ICD coding guidance and clarifications, to address concerns over the ...
Breaking Medicine News(10 mins):